Pliant Therapeutics, Inc.
Extract: Bylaws Amended/Restated (Plain English Desc) from a 8-K on 09/16/2022   Download
SEC Document
SEC Filing

On September 14, 2022, the Board approved the amendment and restatement of the Bylaws of the Company (the “Second Amended and Restated Bylaws”). The Second Amended and Restated Bylaws are effective as of September 14, 2022.

The principal revisions in the Second Amended and Restated Bylaws include (i) additional disclosure and procedural requirements for shareholders to submit nominations or shareholder proposals, (ii) modifications with respect to the conduct of shareholder meetings and the mechanisms for setting their date, time, and place, and (iii) procedures that may be followed in the event that an emergency occurs during which a quorum of the Board or a committee thereof cannot be readily convened.